Patents by Inventor Christophe Villard

Christophe Villard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Administration of avermectin/milbemycin compounds for the treatment of ophthalmic pathologies
    Patent number: 9457038
    Abstract: Administration of at least one compound of the family of the avermectins or of the family of the milbemycins, notably ivermectin, is useful for the treatment of ophthalmic pathologies, including ocular rosacea.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: October 4, 2016
    Assignee: GALDERMA S.A.
    Inventors: Alexandre Kaoukhov, Christophe Villard, Philippe Bouissou
  • INJECTABLE COMBINATION OF ADRENERGIC RECEPTOR AGONISTS WITH FILLERS, FOR DECREASING SKIN REACTIONS DUE TO INJECTION
    Publication number: 20150320743
    Abstract: The present invention concerns an injectable composition comprising a filler or a botulinum toxin and an adrenergic receptor agonist, and its use for diminishing, decreasing or avoiding skin reactions due to injection, specially redness, ecchymosis, bruising, bleeding, erythema, oedema, necrosis, ulceration, swelling and/or inflammation.
    Type: Application
    Filed: May 13, 2015
    Publication date: November 12, 2015
    Inventors: Isabelle Bertholon, Florence Brunel, Benjamin Herbage, Christophe Villard
  • Administration of avermectin/milbemycin compounds for the treatment of ophthalmic pathologies
    Patent number: 8987218
    Abstract: Administration of at least one compound of the family of the avermectins or of the family of the milbemycins, notably ivermectin, is useful for the treatment of ophthalmic pathologies, including ocular rosacea.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: March 24, 2015
    Assignee: Galderma S.A.
    Inventors: Alexandre Kaoukhov, Christophe Villard, Philippe Bouissou
  • ADMINISTRATION OF AVERMECTIN/MILBEMYCIN COMPOUNDS FOR THE TREATMENT OF OPHTHALMIC PATHOLOGIES
    Publication number: 20140256662
    Abstract: Administration of at least one compound of the family of the avermectins or of the family of the milbemycins, notably ivermectin, is useful for the treatment of ophthalmic pathologies, including ocular rosacea.
    Type: Application
    Filed: May 22, 2014
    Publication date: September 11, 2014
    Applicant: Galderma S.A.
    Inventors: Alexandre KAOUKHOV, Christophe VILLARD, Philippe BOUISSOU
  • Administration of avermectin/milbemycin compounds for the treatment of ophthalmic pathologies
    Patent number: 8361974
    Abstract: Administration of at least one compound of the family of the avermectins or of the family of the milbemycins, notably ivermectin, is useful for the treatment of ophthalmic pathologies, including ocular rosacea.
    Type: Grant
    Filed: June 14, 2011
    Date of Patent: January 29, 2013
    Assignee: Galderma S.A.
    Inventors: Alexandre Kaoukhov, Christophe Villard, Philippe Bouissou
  • COMBINATION OF ADRENERGIC RECEPTOR AGONIST ALPHA-1 OR ALPHA-2, PREFERABLY BRIMONIDINE WITH FILLERS, PREFERABLY HYALURONIC ACID
    Publication number: 20120295914
    Abstract: A combination of a quantity of adrenergic receptor agonist ?-1 or ?-2, and preferably product known as brimonidine, with fillers, and preferably with hyaluronic acid, for decreasing skin or cutaneous reactions is described.
    Type: Application
    Filed: May 28, 2010
    Publication date: November 22, 2012
    Applicant: Galderma Research & Development
    Inventors: Christophe Villard, Sylviane Villard
  • INJECTABLE COMBINATION OF ADRENERGIC RECEPTOR AGONISTS WITH FILLERS, FOR DECREASING SKIN REACTIONS DUE TO INJECTION
    Publication number: 20120135937
    Abstract: The present invention concerns an injectable composition comprising a filler or a botulinum toxin and an adrenergic receptor agonist, and its use for diminishing, decreasing or avoiding skin reactions due to injection, specially redness, ecchymosis, bruising, bleeding, erythema, oedema, necrosis, ulceration, swelling and/or inflammation.
    Type: Application
    Filed: May 28, 2010
    Publication date: May 31, 2012
    Applicants: Galderma Research & Development, Symatese
    Inventors: Isabelle Bertholon, Florence Brunel, Benjamin Herbage, Christophe Villard, Sylviane Villard
  • ADMINISTRATION OF AVERMECTIN/MILBEMYCIN COMPOUNDS FOR THE TREATMENT OF OPHTHALMIC PATHOLOGIES
    Publication number: 20120053140
    Abstract: Administration of at least one compound of the family of the avermectins or of the family of the milbemycins, notably ivermectin, is useful for the treatment of ophthalmic pathologies, including ocular rosacea.
    Type: Application
    Filed: June 14, 2011
    Publication date: March 1, 2012
    Applicant: Galderma S.A.
    Inventors: Alexandre KAOUKHOV, Christophe VILLARD, Philippe BOUISSOU
  • ADMINISTRATION OF AVERMECTIN/MILBEMYCIN COMPOUNDS FOR THE TREATMENT OF OPHTHALMIC PATHOLOGIES
    Publication number: 20090093421
    Abstract: Administration of at least one compound of the family of the avermectins or of the family of the milbemycins, notably ivermectin, is useful for the treatment of ophthalmic pathologies, including ocular rosacea.
    Type: Application
    Filed: March 31, 2008
    Publication date: April 9, 2009
    Applicant: GALDERMA S.A.
    Inventors: Alexandre KAOUKHOV, Christophe VILLARD, Philippe BOUISSOU